Cryo-Cell International, Inc.
Moat Score — Cryo-Cell International, Inc.
Total Moat Score
10 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Cryo-Cell's claim as the world's first private cord blood bank (1992) plus AABB/FACT accreditation give it modest brand trust in a niche category, but it holds no dominant patents and faces active litigation risk (the Duke University dispute) that undercuts its scientific/IP credibility. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | At roughly $31 million in TTM revenue and just 76 employees, Cryo-Cell lacks meaningful scale economies versus larger private cord blood banking competitors and has no structural cost edge in processing or storage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Once a family commits to a storage plan there is some tolerance for annual fee increases given how emotionally difficult switching a stored specimen is, but new-customer pricing is constrained by roughly 25 competing national private banks and declining U.S. birth rates. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Cord blood banking has no network effect; one family's decision to store with Cryo-Cell does not make the service more valuable to other families. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | Once cord blood or tissue is collected and cryopreserved at birth, it effectively cannot be moved to a competitor without re-collection (impossible after birth), making the installed base of 250,000+ stored specimens extremely sticky annuity revenue. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The 10-K itself cites roughly 25 competing national private cord blood banks, indicating a fragmented market with no efficient-scale barrier protecting Cryo-Cell's position, despite its first-mover status. |